By Reuters

(Reuters) - Amneal Pharmaceuticals has agreed to acquire biopharma firm Kashiv BioSciences in a ‌cash-and-stock deal worth up to $1.1 billion that will ‌expand the drugmaker's biosimilars business.

The deal will create a fully integrated ​global biosimilars platform, Amneal said on Wednesday, as patents worth more than $300 billion in global biologic drug sales are set to expire over the next decade.

• ‌Under the agreement, ⁠Amneal will pay $375 million in cash and $375 million in equity.

• The deal includes up ⁠to $350 million in potential payments tied to regulatory milestones, possible royalties and funding of Kashiv's operations until the ​transaction closes.

• ​Kashiv develops and manufactures ​biosimilar medicines and has ‌a pipeline of copycat versions of biologic drugs.

• Amneal expects the deal will result in financial benefits worth $400 million to $500 million from synergies.

• The transaction is expected to close in the second half of ‌2026.

• Separately, the New Jersey drugmaker ​reported preliminary revenue of $723 million ​for the first ​quarter, compared with analysts' estimates of $715.3 ‌million, according to data compiled ​by LSEG.

• It ​also raised its 2026 adjusted profit per share forecast to 95 cents to $1.05, from its earlier ​guidance of ‌93 cents to $1.03.

• Amneal shares were up 3% ​in premarket trading.

(Reporting by Siddhi Mahatole in Bengaluru; ​Editing by Jonathan Ananda)

This week on Reuters

• Bond investors propose crisis 'pause clauses' for emerging countries

• How investors buy gold and what fuels the market

• Oil price plunge on US-Iran peace hopes to give rupee, bonds some breather

• Warsh has big ideas. Here are some, in his own words